1/5
THE THERAKOS INSTITUTE

Our professional education platform offers a range of educational initiatives for HCPs in the field.

Visit www.therakosinstitute.eu

to learn more

HEALTHCARE PROVIDERS

Mallinckrodt is focused on providing innovative therapeutic platforms and comprehensive support services to better enable healthcare professionals to deliver optimised ECP Immunomodulation to patients. The THERAKOS™ CELLEX™ Photopheresis system, the only integrated ECP platform, represents our latest advancement in ECP Immunomodulation technology.

PATIENTS AND CAREGIVERS

Mallinckrodt is committed to improving the lives of patients by offering safe and cost-effective therapies that nurture patients’ own immune systems to fight disease and improve health. [1-5]

MALLINCKRODT PHARMACEUTICALS

Learn more about Mallinckrodt Pharmaceuticals by visiting our company website.

References:

  1. Marshall SR. Nat Clin Pract Oncol. 2006 Jun;3(6):302-314.

  2. Bruserud Ø, et al. Cancer Immunol Immunother. 2014;63(8):757-777.

  3. Hart JW, et al. Ther Adv Hematol. 2013;4:320-334.

  4. Suchin KR, et al. J Am Acad Dermatol. 1999;41:980-986.

  5. Das-Gupta E, et al. Bone Marrow Transplant. 2014;49(10):1251-1258.

Mallinckrodt, the 'M' brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a Mallinckrodt company.

 

© 2018 Mallinckrodt. Mallinckrodt Pharmaceuticals is a registered business name of Mallinckrodt plc, which is registered in Ireland as a public limited company with registration number 522227 and has its registered office at Damastown, Mulhuddart, Dublin 15, Ireland.